冠昊生物(300238) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥94,797,135.39, representing a 3.67% increase compared to ¥91,441,252.36 in the same period last year[5] - Net profit attributable to shareholders was ¥14,866,096.67, up 3.30% from ¥14,391,514.75 year-on-year[5] - Basic and diluted earnings per share rose by 20.00% to ¥0.06 from ¥0.05 in the previous year[5] - Total operating revenue for the current period reached ¥94,797,135.39, an increase of 3.9% compared to ¥91,441,252.36 in the previous period[16] - Net profit attributable to the parent company was ¥14,866,096.67, compared to ¥14,391,514.75 in the previous period, indicating a growth of 3.3%[17] Cash Flow - The net cash flow from operating activities increased by 38.64% to ¥15,070,757.80, compared to ¥10,870,539.98 in Q1 2024[5] - The company reported a cash flow from operating activities of ¥19,106,612.73, compared to ¥20,480,417.88 in the previous period, showing a decline of 6.7%[17] - Total cash inflow from operating activities reached ¥107,890,735.24, up from ¥99,050,081.27, indicating an increase of about 8.5%[20] - Cash outflow from investing activities decreased to ¥24,933,790.43 from ¥34,622,805.36, showing a reduction of approximately 28.1%[20] - Net cash flow from financing activities improved to ¥27,235,388.31 compared to ¥15,790,316.69, reflecting an increase of about 72.8%[21] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥764,242,810.86, a 1.30% increase from ¥754,399,831.41 at the end of the previous year[5] - Total liabilities decreased to ¥275,928,969.72 from ¥286,807,928.19, a reduction of 3.0%[15] - The total equity attributable to shareholders increased to ¥557,207,253.00 from ¥542,358,105.24, marking a rise of 2.0%[15] - The company reported a total current asset of CNY 282,432,258.91 as of March 31, 2025, an increase from CNY 265,789,737.12 at the beginning of the period, reflecting a growth of approximately 6.2%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 31,311, with no preferred shareholders[9] - The top shareholder, Beijing Century Tianfu Venture Capital Center, holds 13.58% of the shares, totaling 36,016,266 shares[9] Investments and Expenditures - Long-term equity investments decreased by 98.92% to ¥48,490.18 as a result of the consolidation of an associate into a wholly-owned subsidiary[7] - Research and development expenses were ¥7,798,700.14, slightly up from ¥7,484,200.53, reflecting a year-over-year increase of 4.2%[16] - Cash paid for purchasing goods and services increased to ¥17,166,330.39 from ¥10,396,436.50, representing a rise of approximately 64.9%[20] - Cash paid to employees decreased slightly to ¥33,739,974.43 from ¥34,795,280.36, a decline of about 3.0%[20] Strategic Initiatives - The company is actively pursuing new product development and technological advancements to enhance its market position[12] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[16] - The company is undergoing a stock issuance process, with the application accepted by the Shenzhen Stock Exchange on February 21, 2025[11] Audit Information - The company did not undergo an audit for the first quarter report[22]